NASDAQ:SLN
Silence Therapeutics plc
Silence Therapeutics plc's revenue fell 98.7% in fiscal 2025 to $559,000 while operating margin fell to −16292.8%, its lowest in 4 years. Free cash flow was −$62.3M, −11149.6% of revenue, and the diluted share count rose 2.1%.Summary generated from Silence Therapeutics plc's SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$559,000
Revenue growth−98.7%
Revenue, 5-yr CAGRn/a
Gross margin61.5%
Operating margin−16292.8%
Net margin−15851.9%
ROICn/a
Return on equity−90.3%
Debt / equityn/a
Free cash flow−$62.3M
FCF margin−11149.6%
Share count change+2.1%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 22 | 32 | 43 | 1 |
| Operating income | −61 | −64 | −63 | −91 |
| Net income | −50 | −54 | −45 | −89 |
| Free cash flow | −57 | −50 | −68 | −62 |
Recent filings
- 4Insider transaction report
Aug 13, 2026 - 8-KEntry into a material agreement
Aug 12, 2026 - 8-KRegulation FD disclosure
Aug 10, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 8-KResults of operations and financial condition
Aug 10, 2026 - 8-K/AAmended director or officer change
Jul 16, 2026 - 4Insider transaction report
Jul 7, 2026 - 8-KRegulation FD disclosure
Jun 23, 2026